Photo: Nikolay Titov / “Kommersant”
Russians with rare diseases are faced with a shortage of necessary drugs, which were introduced by the Ministry of health list of drugs for the treatment of coronavirus and complications from COVID-19. This is related to several patient organizations, reports “Kommersant”.
Difficulties arose in patients with rheumatoid arthritis and systemic lupus erythematosus, told in Russian rheumatologic Association “Nadezhda” — patients are unable to some drugs neither state benefits nor to buy. With the difficulties faced by patients with systemic scleroderma — they can’t afford the medicine “Plaquenil” after the health Ministry recommended it for the treatment of coronavirus: he disappeared from pharmacies, as its centrally purchased by the state.
The head of the Russian public organization of patients with multiple sclerosis Yan Vlasov said that in the next version of the recommendations of the Ministry of health can appear drugs to patients with multiple sclerosis, then a shortage of medicines and they will face.
The Ministry of health sees the risk of shortage of medicines on the Russian market, writes “Kommersant”, — this follows from the draft government resolution on the extension of the powers of Roszdravnadzor in the monitoring not only of range but also the volume of medicines from the list vital and important. A source in one of the pharmaceutical companies explained “Kommersant” that the companies are invited to send information about the production and supply of their products by e-mail, however, as stated in the development Center of advanced technologies (CRPT), the markings will make the process more efficient, the government will be able to monitor the availability, adequacy and origin of drugs in real time.
Video, photo All from Russia.